<DOC>
	<DOCNO>NCT02867891</DOCNO>
	<brief_summary>In trial investigator evaluate outcome 4 pre‐defined group individual accord therapeutic intervention . The investigator determine outcome group monitor survival response rate patient FLT3-ITD AML relapse allo-HSCT .</brief_summary>
	<brief_title>Sorafenib In Relapse FMS-like Tyrosine Kinase 3 ( FLT3 ) -Internal Tandem Duplication ( ITD ) AML Trial</brief_title>
	<detailed_description>The preliminary data investigator demonstrate potent activity Sorafenib combine Donor lymphocyte infusion ( DLI ) relapse FLT3-ITD+ Acute myeloid leukemia ( AML ) allogeneic hematopoietic cell transplantation ( allo-HSCT ) . The investigator therefore launch observational multicenter trial . The outcome assess 4 pre‐defined group individual accord therapeutic intervention ( chemotherapy-alone-group , chemotherapy/DLI group , sorafenib alone group sorafenib/DLI group ) . The specific intervention subject study assign individual transplant center . The investigator determine outcome group monitor survival response rate ( complete remission , disease burden reduction , response ) patient FLT3-ITD AML relapse allo-HSCT .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Histology/PCR proven relapse FLT3ITD+ AML alloHSCT Age ≥18 year Treatment either chemotherapyalone , chemotherapy/DLI , sorafenib alone sorafenib/DLI Written inform consent Ability understand nature study study relate procedure comply Age &lt; 18 year Lack inform consent Patients classify one 4 group : chemotherapyalonegroup , chemotherapy/DLI group , sorafenib alone group sorafenib/DLI group</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>FLT3-ITD</keyword>
	<keyword>AML</keyword>
	<keyword>allo-HSCT</keyword>
</DOC>